Novo A/S, the holding company of Denmark's Novo Nordisk, has acquired Xellia Pharmaceuticals of Norway in a deal valued at $700 million.Xellia was spun-out from Alpharma in 2008 and was principally owned by UK equity group 3i. It specializes on anti-infective products for multi-drug resistant infections and is "a world-leading supplier of vancomycin and colistimethate sodium." Read the full story